Dr. Bryan K. Dunn, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Brody School of Medicine at East Carolina University (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Brody School of Medicine at East Carolina University
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 2011-00986 -
Critical Care Medicine (Internal Medicine) Physician
NC license 2011-00986
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ecu Health Medical Center Greenville, NC
- Carteret General Hospital Morehead City, NC
- Vidant Roanoke Chowan Hospital Ahoskie, NC
- Ecu Health Bertie Hospital Windsor, NC
Medical groups
- Vidant Medical Group LLC (1,012 clinicians)
- East Carolina University (499 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 224
- Services billed
- 707
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 251 | 115 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 87 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 42 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 39 | 37 |
| Ultrasonic guidance for blood vessel access | 36 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 21 | 20 |
| Insertion of artery tube for blood sampling or infusion through skin | 17 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Greenville, NC | 241 |
| Prednisone Other prescribers in Greenville, NC | 179 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Greenville, NC | 84 |
| Montelukast Sodium Other prescribers in Greenville, NC | 73 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Greenville, NC | 60 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Greenville, NC | 36 |
| Levofloxacin Other prescribers in Greenville, NC | 34 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Greenville, NC | 29 |
| Azithromycin Other prescribers in Greenville, NC | 28 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Greenville, NC | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 29 payments worth $6,069 in total to this clinician.
| Genzyme Corporation | $3,786 |
|---|---|
| Medtronic, Inc. | $1,585 |
| AstraZeneca Pharmaceuticals LP | $656 |
| Ethicon Inc. | $22.27 |
| Shionogi Inc | $19.88 |
| Compensation for services other than consulting (speaking, faculty) | $3,978 |
|---|---|
| Travel and Lodging | $1,546 |
| Food and Beverage | $545 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,728 |
| Medtronic, Inc. Sep 5, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $755 |
| AstraZeneca Pharmaceuticals LP Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Medtronic, Inc. Oct 8, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $175 |
| Medtronic, Inc. Oct 9, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $175 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $117 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $75.00 |
| Medtronic, Inc. Oct 11, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $62.94 |
| Medtronic, Inc. Oct 9, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $51.10 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionResearch Related Service | $36.00 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Oct 11, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $62.94 |
| Medtronic, Inc. Oct 9, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $175 |
| Medtronic, Inc. Oct 9, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $51.10 |
| Medtronic, Inc. Oct 9, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $14.92 |
| Medtronic, Inc. Oct 8, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $175 |
| Medtronic, Inc. Oct 8, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $14.92 |
| Medtronic, Inc. Sep 5, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $755 |
| Medtronic, Inc. Sep 5, 2025 | Travel and Lodging ILLUMISITE · Interventional Lung Solutions · travel to Minneapolis, MN · in-kind | $35.07 |
| AstraZeneca Pharmaceuticals LP Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Genzyme Corporation Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,728 |
| Genzyme Corporation Jun 26, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Greenville, NC | $4.20 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $117 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $75.00 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionResearch Related Service | $36.00 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionResearch Related Service | $30.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $87,452 in research payments for these studies, mostly to the institutions running them.
- The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
GlaxoSmithKline, LLC. - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.